At Berkshire Hathaway's (BRK-B, BRK-A) annual shareholders meeting over the weekend, chairman and CEO Warren Buffett, 94, announced that he will step down and be succeeded by Berkshire Hathaway Energy Chair Greg Abel at the end of the year. Palantir (PLTR) is set to publish its first quarter earnings after Monday's market close. Hims & Hers Health (HIMS) announced that former Amazon (AMZN) executive Nader Kabbani will be joining the telehealth company as its new COO. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. Video Transcript 00:00 Speaker A It's now time for some of today's trending tickers. This morning we are watching Berkshire Hathaway, previewing earnings for both Palantir and Hims & Hers. First up, Berkshire trending after a big weekend of news out of the company's annual shareholder meeting here, including Warren Buffett tapping a new successor. We did know energy executive Greg Abel was going to be taking over. That is set to occur at the end of this year. Shares are lower today, on track for their worst day since April 4th. They're down just about 5%. Adam Johnson is still here with me to provide some commentary. And Adam, I know this isn't a name that you own, but how do you think about it? 00:41 Adam Johnson Right. It's a stock. It's a value name. I'm a growth investor. 00:44 Speaker A Growth guy, yep, yep. 00:47 Adam Johnson Yeah, anyone who's surprised that Warren Buffett, God bless him, is retiring, um, needs to just pick up a newspaper and I mean, come on. How old is Mr. Buffett? 00:57 Speaker A He's in his 90s, yeah. 00:58 Adam Johnson He's in his 90s. And we're going to be surprised that he's retiring. Maybe a little sad. I'm only surprised he didn't retire a decade ago. I mean, God bless him, a legend, a gentleman, a thinker, a leader and inspiration for so many. 01:11 Speaker A Does he frame your thinking on investing at all? Has he influenced how you think? 01:16 Adam Johnson No. You're very different thinkers, yeah. 01:18 Speaker A You're very different. 01:19 Adam Johnson He is a value investor. He, for example, Bank of America, one of his big positions. You buy Bank of America when it trades at a discount to book value and you sell it when it gets to about 1.5 or 1.6 times book value, right? A value investor says, here, it's a buy, here, it's a sell, and you're playing that differential. And value investors sort of go in and out of the same name, perhaps, you know, multiple times as the stock moves around with the business cycle. I don't do that. I'm trying to find a wonderful young company or in some cases, a bigger mature company that is growing at double digits. And by double digits, I want to find earnings growth of 20 to 30%, maybe more in the case of, say, an Nvidia or AI stocks. And then I try to figure out what the, uh, what the cash flow will be three to five years from now, discount all that future cash flow back to the present, and then put a multiple, a PE multiple on that. And that's, if I say, if I do that analysis, and I find that the stock is trading at, um, a price that I think is a fraction of where it ought to trade, I buy it. And then when it gets to my target, I always sell a third. Right. And then I rerun the analysis. And if I can get to a higher target, I hold on to it. So that's the way I invest, very different from what Mr. Buffett does. 03:00 Speaker A Well, we're going to talk about a potential name that fits somewhat into that framework here. We're going to talk about Palantir shares wavering just a bit this morning. Earnings out after the close. Analysts are expecting a massive 36% year-over-year revenue jump. The stock down about 1% right now. Investors gearing up to get insight into AI demand and defense spending. I know this is the type of name that you could have added to. It's a growth stock, but it is not in your positions. 03:27 Adam Johnson Yes. Yeah. 03:29 Speaker A Why? 03:29 Adam Johnson I stared at that stock every day when it was at eight bucks and thought, can I buy this thing? And the reason I didn't, and I was wrong not to buy it, but the reason I didn't is that at that point, um, their business model was lopsided, by which I mean, they would go into a company, and they would get a huge upfront payment, which was typically 90% of the revenue they would get from that client. And then over time, eight months after they installed the AI platform into that company, they would get a small subscription, which was just 10%. It should be the other way around. Get 10% up front, and then get the 90% on the back end spread out quarter after quarter after quarter. That's sustainable cash flow. They didn't do that. They have since switched, um, but the stock had already run. And at this point, it's trading at, I don't know, 200 times earnings. That's just, I know I'm a growth guy, but 200 times earnings is an awful lot. So, no, I don't own Palantir, and that's specifically why. It was about the cash flow of the business. 04:47 Speaker A All right. Well, let's also talk about another name here, Hims & Hers announcing a C-suite shakeup ahead of its earnings out after the close. The health company tapping an Amazon executive as its new chief of operations as it does plan to expand into areas like blood testing. Obviously, Hims & Hers has been on a bit of a run over the course of the past couple of months. They are providing a compounded GLP-1 drug to consumers recently, teaming up with Big Pharma as well in an attempt to reach consumers more broadly with these drugs. How are you thinking about a company like this? 05:20 Adam Johnson Yeah. 05:21 Adam Johnson So I don't own this one because it's feast or famine. And it's very hard to try to figure out whether this company's going to make money a year from now, two years from now. And here's why. As a compounding pharmacy, they are allowed to compound or fabricate or make drugs that are on allocation because we can't make enough. Great example, Wegovy, Ozempic, right? Uh, drugs made by Novo Nordisk that help diabetes and weight loss. Well, there was so much demand for these drugs that Novo couldn't make enough of them. So compounding pharmacies were allowed to basically just look at the recipe and say, oh, here's how we make it. And then they make it and sell it. Um, but when the drug comes off allocation and those drugs are no longer on allocation, Novo can make enough of them. They're not allowed to make them anymore. Right. Right? So it's feast or famine. That's a hard business to own. I mean, more recently, they've gotten into the sex drugs market, right? You know, Cialis, etc. So if you're on your Instagram feed and you keep seeing, you know, all these ads, you know, better, better sex life, go to Hims & Hers. Yeah. Hair loss supplements. All kinds of things. Yes. Yeah, I'm not a buyer of this company. 07:04 Speaker A Yeah, and to your point, we definitely see a lot of volatility around any announcement from the FDA on GLP-1s. So it's a great framework there for those investors. 07:13 Adam Johnson Yes. Related Videos 01:59 Mag 7 earnings show 'the AI story remains intact,' analyst says Yahoo Finance Video • 25 minutes ago 01:03 Film tariffs, On Semiconductor earnings, Skechers to go private Yahoo Finance Video • 28 minutes ago 10:36 Apollo CEO weighs in on US investments, trade tariffs Yahoo Finance Video • 42 minutes ago 06:12 Market Outlook with Maria Vassalou Bloomberg • 48 minutes ago View Comments
Buffett succession, Palantir earnings preview, Hims COO pick
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...